Lilly Stock Slips as Patients Regain Weight After Stopping Zepbound

Lilly Stock Slips as Patients Regain Weight After Stopping Zepbound

Source: 
BioSpace
snippet: 

Eli Lilly’s stock slipped 4% in premarket trading Monday after a study published in the scientific journal JAMA found patients on its weight loss drug regained “substantial” weight after stopping treatment.